Skip to main content
Premium Trial:

Request an Annual Quote

ICR, London to Create Tumor Profiling Center

NEW YORK (GenomeWeb News) – The Institute for Cancer Research, London plans to launch a new center that will conduct genomic profiling of patients' cancer tumors, and it wants to raise £3.2 million ($5.1 million) to fund the venture.

ICR said yesterday that the money it raises for the new Tumour Profiling Unit will be used to attract scientific expertise to the center and to buy new equipment and to outfit its labs.

The center will help to advance ICR's personalized medicine-centered scientific strategy, which is based on three themes: genetics and epidemiology, molecular pathology, and therapeutic development.

The institute pursues its goals by working with The Royal Marsden cancer center and the Biomedical Research Centre for Cancer, by balancing its portfolio between basic and applied science, and by developing treatments based on patient and tumor genomes.

ICR, a college of the University of London, also partners with funding organizations that include Cancer Research UK, Breakthrough Breast Cancer, and the Wellcome Trust. In 2011, its budget totaled £87.4 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.